Glenmark Pharmaceuticals, a research-led global integrated pharmaceutical company, announced that the company has been listed in the Dow Jones Sustainability Index (DJSI) under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally, with only the top-ranked companies in terms of Corporate Sustainability within each industry featured in the index.
The DJSI analyses companies on their corporate economic, environmental, and social performance to assess issues such as but not limited to corporate governance, risk management, environmental policy and management systems, supply chain management, occupational health and safety, labor practices, innovation, and cybersecurity amongst others. Inclusion in this list is considered highly prestigious by global investors, financial analysts, and other stakeholders and serves as a benchmark for investors who integrate sustainability considerations into their portfolios.
“DJSI is universally acknowledged as one of the most respected and accepted sustainability benchmarks and so it is a matter of great pride for us to be included in the list for the third consecutive year. We recognize that sustainability is a continual process that encompasses our operations, stakeholders, communities and the planet at large. Our inclusion in this list underscores our consistent performance across all sustainability indicators,” said Glenn Saldanha, chairman, and managing director, Glenmark Pharmaceuticals.
Over 800 companies across sectors from the emerging markets were assessed, out of which 100 made it to the prestigious index this year, including 11 from India. Glenmark is one of the only two companies from the Indian Pharmaceutical sector to be featured in the DJSI Emerging Markets 2020. Glenmark is ranked 13th among global pharmaceutical companies.
Glenmark Pharmaceuticals (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 80 pharma and biotech companies globally in terms of revenue (SCRIP 100 Rankings published in the year 2019). Glenmark is a leading player in discovering new molecules, both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various clinical development stages and is focused on oncology, dermatology, and respiratory.
The company has a significant presence in the branded generics markets across emerging economies, including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America, and India.